Biocon Cautiously Optimistic On Earnings Prospects Amid Slower Approvals
Executive Summary
India’s biggest biotech firm has said it is “cautiously optimistic” about its performance this financial year after fourth-quarter net profit slid due to an exceptional item in the previous year, but reports progress on multiple fronts for its large biosimilar portfolio.